Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
NCT01285609
Completed
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2020
Locations: Sharp Memorial Hospital, San Diego, California
Conditions: Lung Cancer - Non Small Cell Squamous
Register for Updates
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
NCT00617942
Completed
Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable HER2+ (stage IIa-IIIb) breast cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/28/2020
Locations: City of Hope, Duarte, California
Conditions: Breast Cancer
Register for Updates
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
NCT01803282
Completed
The primary objective of the study is to determine the maximum tolerated dose of andecaliximab monotherapy and to evaluate the safety and tolerability of andecaliximab (formerly GS-5745) alone and in combination with chemotherapy. The study consists of 2 parts (Parts A and B). Participants can only qualify for and participate in 1 part. Part A is a sequential dose escalation to determine the maximum tolerated dose of andecaliximab in participants with advanced solid tumors that are refractory... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2020
Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +4 locations
Conditions: Pancreatic Cancer, Non-small Cell Lung Cancer, Esophagogastric Cancer, Colorectal Cancer, Breast Cancer
Register for Updates
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
NCT02116959
Terminated
The purpose of this study is to test the safety of the treatment combination of alternating standard chemotherapy and another (melphalan) chemotherapy at different interval schedules. Researchers want to find out what effects, good and/or bad, the treatment combination has on the patients and their retinoblastoma.
Gender:
ALL
Ages:
Between 3 months and 18 years
Trial Updated:
04/14/2020
Locations: University of California, San Francisco, San Francisco, California
Conditions: Advanced Intra-Ocular Retinoblastoma, Retinoblastoma
Register for Updates
Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer
NCT00006229
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether paclitaxel and carboplatin are more effective with or without BMS-275291 for non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of paclitaxel and carboplatin with or without BMS-275291 in treating patients who have advanced or metastatic non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/02/2020
Locations: Scripps Clinic, La Jolla, California
Conditions: Lung Cancer
Register for Updates
M6620 First in Human Study
NCT02157792
Completed
An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2020
Locations: Sharp Memorial Hospital, San Diego, California +1 locations
Conditions: Advanced Solid Tumor
Register for Updates
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00661193
Completed
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with carboplatin and paclitaxel may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well erlotinib works when given alone or together with carbop... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/19/2020
Locations: Kaiser Permanente - Deer Valley, Antioch, California +35 locations
Conditions: Lung Cancer
Register for Updates
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT02199171
Completed
This phase I trial studies the side effects and best dose of heated carboplatin given into the abdomen at the time of surgery in treating patients with stage II-IV ovarian, fallopian tube, or peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating oxaliplatin and infusing it directly into the area around the tumor during su... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/29/2020
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
Register for Updates
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
NCT01653470
Completed
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2020
Locations: Usc/Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Cancer
Register for Updates
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
NCT02383212
Completed
This is a phase 1, open-label, multicenter, ascending-dose escalation study of cemiplimab, alone and in combination with other anti-cancer therapies in patients with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2020
Locations: City of Hope National Medical Center, Duarte, California +3 locations
Conditions: Advanced Cancer, Advanced Malignancies
Register for Updates
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
NCT02358200
Terminated
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine the recommended Phase II dose of the combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/07/2020
Locations: University of California San Francisco, San Francisco, California
Conditions: Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
Register for Updates
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
NCT01310244
Completed
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2020
Locations: Sarcoma Oncology Center, Santa Monica, California
Conditions: Stage IV Non-small Cell Lung Cancer
Register for Updates